Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Noile-Immune BiotechTSE:4893 -0.71%45 Cash Ratio is 41.65 as of Jun. 2026, which is 19% below its 10-year median of 51.42. GuruFocus rates TSE:4893 with a GF Score™ of 45/100 and a GF Value™ of 円15.41 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,380 Biotechnology companies, Noile-Immune Biotech ranks better than 98.48% on this metric.
Noile-Immune Biotech has a Cash Ratio of 41.65. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Noile-Immune Biotech's Cash Ratio or its related term are showing as below:
TSE:4893'
s Cash Ratio Range Over the Past 10 Years
Min: 13.49 Med: 51.42 Max: 68.64
Current: 41.65
During the past 6 years, Noile-Immune Biotech's highest Cash Ratio was 68.64. The lowest was 13.49. And the median was 51.42.
TSE:4893's Cash Ratio is ranked better than 98.48% of 1380
companies
in the Biotechnology industry
Industry Median: 2.96
vs TSE:4893: 41.65
Noile-Immune Biotech (TSE:4893) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Noile-Immune Biotech Cash Ratio Related Terms
Noile-Immune Biotech Cash Ratio Historical Data
* Premium members only.
The historical data trend for Noile-Immune Biotech's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4893 vs VRTX, REGN, MRNA: Cash Ratio Comparison
For the Biotechnology subindustry, Noile-Immune Biotech's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Noile-Immune Biotech Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Noile-Immune Biotech's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Noile-Immune Biotech's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Noile-Immune Biotech (TSE:4893) has a Cash Ratio of 41.65 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Noile-Immune Biotech and its competitors. This is 19% below median its historical median of 51.42. Over the past decade, Noile-Immune Biotech's Cash Ratio has ranged from 13.49 to 68.64. According to the industry distribution chart, Noile-Immune Biotech ranks #21 out of 1380 companies in the Biotechnology industry, placing it in the top 1.5%.
Is Noile-Immune Biotech's Cash Ratio too high?
Noile-Immune Biotech's current Cash Ratio of 41.65 is 19% below median its 10-year median of 51.42. Over the past 10 years, this metric has ranged from a low of 13.49 to a high of 68.64. The Biotechnology industry median Cash Ratio is 2.96. Noile-Immune Biotech's value of 41.65 is 1307.1% above this industry median. Based on the distribution chart, Noile-Immune Biotech ranks #21 out of 1380 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Noile-Immune Biotech has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Noile-Immune Biotech's Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Noile-Immune Biotech ranks #21 out of 1380 companies for Cash Ratio. This places Noile-Immune Biotech in the top 2% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.96. Noile-Immune Biotech's value of 41.65 is 1307.1% above this benchmark. Historically, Noile-Immune Biotech's own Cash Ratio has ranged from 13.49 to 68.64 over the past decade. While the company's 10-year median is 51.42 vs. the industry median of 2.96, Noile-Immune Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.96, based on 1,380 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Noile-Immune Biotech's current Cash Ratio of 41.65 is 1307.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Noile-Immune Biotech and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Noile-Immune Biotech's current Cash Ratio is 41.65, which is 19% below median its own 10-year median of 51.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Noile-Immune Biotech stock overvalued right now?
Based on GuruFocus' analysis, Noile-Immune Biotech (TSE:4893) is currently considered Significantly Overvalued. The stock's GF Value™ is 円15.41, compared to a current price of 円139.00 — trading 802% above its estimated fair value. The current Cash Ratio is 41.65, which is 19% below median its 10-year median of 51.42 and 1307.1% above the Biotechnology industry median of 2.96. Noile-Immune Biotech's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Noile-Immune Biotech (TSE:4893), the current Cash Ratio is 41.65 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Noile-Immune Biotech (TSE:4893) Overvalued in 2026?
Based on GuruFocus' analysis, Noile-Immune Biotech stock appears to be overvalued.
The current stock price of 円139.00 is trading 802% above its estimated GF Value™ of 円15.41.
GuruFocus considers Noile-Immune Biotech to be Significantly Overvalued.
Key valuation signals for TSE:4893:
Cash Ratio: 41.65 (19% below median its 10-year median of 51.42)
GF Value™: 円15.41 vs. price of 円139.00 (802% above fair value)
Industry Position: 1307.1% above the Biotechnology median (#21 of 1380)
No single metric tells the full story. See the TSE:4893 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Noile-Immune Biotech Inc is engaged in the development of CAR-T cell therapy for solid cancers using its proprietary technology. The company's development pipeline and collaborative projects with other companies include different product candidates such as NIB102, NIB103, NIB104, ADAP01, AUTL01, etc. It operates in a single segment, the cancer immunotherapy drug discovery business.
45GF Score
Get the complete analysis for TSE:4893
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4893 has been successfully added to your 
